Protection of hematopoietic stem cell recipients from infection remains challenging because of severe immunosuppression after transplantation. In patients with hepatitis B virus (HBV) infection prior to transplantation, the risk of HBV reactivation 5 years after transplantation was 70-86%. 1, 2 To overcome HBV reactivation, active immunization of donors and early post-transplant vaccination of recipients has been suggested. 3, 4 This recommendation is based on the fact that adoptive immune transfer from HBVvaccinated donors was detected after hematopoietic stem cell transplantation. 3, [5] [6] [7] [8] [9] However, protection from reactivation depended on vigorous HBV immunity in the donor. 3, 10 Therefore, donors should optimally receive more than one immunization, a rather high Ag dose and a highly immunogenic vaccine. As clearance from HBV infection is dependent on effective T-cell immunity, the protection of recipients can be estimated better if their HBV-specific cellular immune response is known. However, cellular HBV immunity had not been determined in a previous study showing that donor vaccination can control HBV infection in hematopoietic stem cell recipients. 3 We here present two effective strategies to select the optimal donor for hematopoietic stem cell recipients at risk of HBV reactivation or persistence of chronic HBV infection. Donors could either be electively vaccinated with highly immunogenic vaccines (for example, third generation vaccines containing PreS1, PreS2 and S HBV Ags 11 ) or donors with strong HBV immunity after vaccination could be selected. Our study was approved by the local ethics committee and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects.
Humoral and cellular HBV immunity were measured as described previously. 8, 11, 12 To assess HBV-specific T-cell proliferation and interferon-γ production, peripheral blood mononuclear cells were incubated with the PreS1, PreS2 and S HBV Ags (unformulated bulk). A stimulation index (SI, quotient of HBVspecific and non-stimulated proliferation) ⩾ 2.5 was considered positive. 12 ELISpot results were generated as HBV-specific minus non-stimulated interferon-γ production. 11 The cutoff value was defined as an HBV-specific value that was threefold higher than the non-stimulated control.
Patient #1, a 43-year-old male with Non-Hodgkin lymphoma, suffered from reactivation of HBV infection 5 months prior to PBSC transplantation (PBSCT) during chemotherapy. Chemotherapy was started 8 months prior to PBSCT and led to PR. Owing to HBV reactivation, he received lamivudine and was transplanted after HBV DNA became undetectable. The first stem cell donor was his HLA-identical, 40-year-old sister. As she was HBV-naïve, we actively immunized her four times (day 0, week 2, week 4 and month 5) with 20 μg of a vaccine containing PreS1, PreS2 and S HBV Ags (Bio-Hep-B, Berna Biotech, Bern, Switzerland). She developed humoral and cellular HBV immunity prior to PBSCT (Figure 1 , patient #1). The corresponding recipient displayed humoral HBV immunity prior to PBSCT (90 IU/L anti-HBs); but cellular immunity was absent (SI of 0.5). HBV DNA was undetectable prior to transplantation ( Figure 2 , patient #1). One month after PBSCT, humoral HBV immunity increased in the recipient (633 IU/L antiHBs). A maximum was reached at month 19 after transplantation (1483 IU/L anti-HBs). At the same time, the recipient had detectable cellular HBV immunity (SI of 4.8 and 8.5 spots increment); indicating that HBV infection was controlled by donor T cells. HBV DNA remained negative until month 27 post transplantation. However, the patient relapsed at month 20. Thereafter, HBV immunity declined. Twenty-seven months after the initial transplantation, the patient received a second graft from his HLA-haploidentical, 49-year-old sister (CD3/CD19-depleted graft). This sister had resolved HBV infection (17 IU/L anti-HBs, anti-HBc-positive, HBsAg-and HBV DNA-negative). After the second transplantation, HBV DNA became intermittently positive. The recipient showed a short-term, minor increase in anti-HBs antibodies (88 IU/L). In the follow-up, antibodies became undetectable. Fifteen months after the second transplantation, the patient relapsed again. Four months thereafter, he died from pneumonia.
Patient #2, a 49-year-old male, suffered from myelodysplastic syndrome and acute HBV infection 4 months prior to PBSCT. He was also treated with lamivudine and was transplanted after HBV DNA became undetectable. His HLA-identical, HBV-naïve sister was vaccinated four times (day 0, day 10, day 24 and month 3) by her general practitioner with 20 μg of a German standard vaccine containing the HBV S Ag (Engerix-B, GlaxoSmithKline, Munich, Germany). He had detectable anti-HBs antibodies prior to and post transplantation (Figure 1, patient #2 ). By means of Ab titers, it cannot be determined whether anti-HBs had been transferred with the graft. After stem cell transplantation, the recipient remained HBV DNA-negative and cleared his HBV infection (for example, HBsAg-negative, 19 IU/L anti-HBs, anti-HBc-positive at month 5) (Figure 2 , patient #2). Anti-HBs antibodies in the recipient declined until month 5 after PBSCT. From month 5 to month 9, anti-HBs antibodies slightly increased. The patient suffered from acute and thereafter from limited chronic GvHD and was treated by cyclosporine A. At month 9, GvHD was well controlled and low-dose treatment with cyclosporine was sufficient. After month 9, lamivudine treatment was stopped. At month 10, there was a strong increase to an anti-HBs titer exceeding 1000 IU/L, HBV DNA in the peripheral blood remained negative. Most likely, a combination of omitting antiviral treatment-leading to a 'booster' by HBAg persisting outside the peripheral blood-and reconstitution of immune function led to the increased anti-HBs titer. At year 9 (month 112) after transplantation, HBsAg remained negative and humoral HBV immunity was detectable (18 IU/L anti-HBs-and anti-HBc-positive). Cellular HBV immunity could also be measured (SI of 5.5 and 6 spots increment); indicating long-term control of HBV infection.
Patient #3, a 51-year-old female with secondary acute myeloid leukemia after myelodysplastic syndrome, was chronically infected with HBV. Her donor was an unrelated female, previously immunized with an HBV vaccine containing S Ag. The donor was selected based on her high anti-HBs titer (265 647 IU/L) and was phenotypically HLA-identical (Figure 1, patient #3) . The patient was furthermore treated by entecavir from month 3 pretransplantation until month 3 post transplantation. Prior to PBSCT, no anti-HBs antibodies could be detected in the patient. At month 1 after PBSCT, however, she displayed humoral and cellular HBV immunity (588 497 IU/L anti-HBs, SI of 5.4 and 8 spots increment). She cleared her chronic HBV infection and was HBV DNA-negative ( Figure 2 , patient #3). At month 3, humoral HBV immunity further increased (1 301 100 IU/L anti-HBs). Cellular HBV immunity, however, was undetectable (SI of 1.0 and 2 spots increment) and HBV DNA remained negative. Most likely, after PBSCT, HBsAg had persisted outside the peripheral blood and 'boosted' anti-HBs production. Unfortunately, the patient relapsed at month 3 after transplantation. She was treated with three courses of donor leukocyte infusions (month 8-11). At month 11, she developed GvHD of the liver, humoral HBV immunity was lost and HBsAg re-appeared. Treatment with entecavir was started again. At month 12, the patient presented with cachexia and died from relapse. In summary, HBV infection could be controlled after patients received grafts from HBV-vaccinated donors. But following relapse, HBV immunity was lost. The study indicates that the optimal donor for an HBV-infected recipient is a vaccinated person with humoral and cellular HBV immunity. Third generation HBV vaccines are especially useful when time is short to de novo induce sufficient HBV immunity. As compared with conventional (second generation) HBV vaccines, HBV immunity develops earlier and immunity is stronger after application of the third generation vaccines. 11, 13, 14 In the current study, anti-HBs clearly increased in patient 1 after receiving a graft from the donor vaccinated with a third generation vaccine. On the contrary, even a decline in anti-HBs titers was observed in patient 2 receiving a graft from the donor vaccinated with a conventional HBV vaccine. Nevertheless, patient 2 remained HBsAg-negative for 9 years. Donor vaccination may have helped to control HBV infection. If time is very short, it would be optimal to select a donor with high anti-HBs titer and to apply one 'booster' immunization. One week after 'booster' immunization, peak HBV immunity is expected and harvesting of hematopoietic stem cells would be most promising to achieve an HBV-specific immune transfer. However, if de novo or 'booster' vaccination of the donor is not possible, long-term antiviral prophylaxis and vaccination of the recipient would be an alternative. 4 Extending current literature, 3 we were able to show that after transplantation cellular HBV immunity was detectable in previously HBsAg-positive stem cell recipients. This is important because HBV-specific T cells are a prerequisite to control HBV infection. As hematopoietic stem cell recipients usually have impaired T-cell function for many months, 15 the detection of HBVspecific cellular immunity only 1 month after transplantation is remarkable.
In conclusion, we recommend vaccinating donors for HBVinfected stem cell recipients with highly immunogenic vaccines or to apply a single 'booster' immunization in pre-vaccinated donors. Donor vaccination can help to control HBV infection in the recipient and should be considered as a highly efficient therapeutic option.
